Uptrend on the daily chart: above its 200-day average, below its 50-day · 50-day above the 200-day · SuperTrend up since Aug 21 · inside the Ichimoku cloud · RSI 38 · MACD below its signal
| 5.73 | 52-week high | +20.63% |
| 5.57 | Previous month high | +17.16% |
| 5.40 | R3 (classic) | +13.75% |
| 5.33 | Previous week high | +12.21% |
| 5.19 | R2 (classic) | +9.19% |
| 5.04 | R1 (classic) | +6.18% |
| 5.00 | Previous month low | +5.26% |
| 4.97 | Previous day high | +4.63% |
| 4.83 | Pivot | +1.61% |
| 4.75 | Previous week low | +0.00% |
| 4.75 | Price now | |
| 4.68 | S1 (classic) | −1.40% |
| 4.61 | Previous day low | −2.95% |
| 4.47 | S2 (classic) | −5.96% |
| 4.32 | S3 (classic) | −8.98% |
| 3.10 | 52-week low | −34.74% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $592.4K | 0.00% | 116.62K | +527% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PYPD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for PYPD.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 5.5 | -7.2 | 3.1 | 2.7 | 4.9 | 7.6 | -15.6 | 19.8 | 2.5 | -9.9 | +9.4% | ||
| 2025 | -5.9 | 12.9 | -16.1 | 5.2 | -1.8 | 26.1 | -4.8 | -0.3 | -0.4 | 14.8 | 3.1 | 9.9 | +42.8% |
| 2024 | 65.8 | -14.9 | -14.2 | 3.7 | -5.7 | -4.4 | -16.0 | -1.7 | -3.1 | -7.0 | 4.4 | -9.0 | −20.0% |
| 2023 | 10.0 | -12.8 | -31.3 | -8.7 | -7.1 | -6.4 | -1.4 | -16.7 | -49.9 | -8.2 | 13.5 | -19.1 | −81.9% |
| 2022 | -22.3 | -9.4 | 35.1 | -11.2 | 10.9 | -13.8 | 8.8 | 19.2 | -80.6 | -21.4 | -14.1 | -11.6 | −87.8% |
| 2021 | -5.2 | 18.8 | -17.9 | 0.4 | 3.3 | -4.7 | -9.8 | 16.0 | -17.9 | -8.6 | -4.4 | -15.6 | −42.0% |
| 2020 | -22.5 | -14.0 | -8.4 | -5.4 | 14.1 | -16.7 | −45.1% |
TimeframesDown on the hourly, daily and monthly, mixed on the weekly.
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Buy / hold / sell counts